Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low B-cell content is associated with a CD73-low tumour microenvironment and unfavourable prognosis in classic Hodgkin lymphoma.
Grund J, Iben K, Reinke S, Bühnen I, Plütschow A, Müller-Meinhard B, Garcia Marquez MA, Schlößer HA, von Tresckow B, Kellermeier F, Borchmann P, Engert A, Bröckelmann PJ, Klapper W. Grund J, et al. Among authors: buhnen i. Br J Haematol. 2023 Jun;201(6):1097-1102. doi: 10.1111/bjh.18762. Epub 2023 Mar 15. Br J Haematol. 2023. PMID: 36921595
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.
Bröckelmann PJ, Bühnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth TV, Schaub V, Kerkhoff A, Mathas S, Bormann M, Dickhut A, Kaul H, Fuchs M, Kobe C, Baues C, Borchmann P, Engert A, von Tresckow B. Bröckelmann PJ, et al. Among authors: buhnen i. J Clin Oncol. 2023 Feb 20;41(6):1193-1199. doi: 10.1200/JCO.22.02355. Epub 2022 Dec 12. J Clin Oncol. 2023. PMID: 36508302 Clinical Trial.
Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis.
Momotow J, Bühnen I, Trautmann-Grill K, Kobbe G, Hahn D, Schroers R, Heinrich B, Gaska T, Forstbauer H, Schmidt B, Boger R, Hüttmann A, Heil G, Kraemer DM, Krüger W, Zeremski V, Grobe N, Jentsch-Ullrich K, Griesinger F, Fuchs M, von Tresckow B, Borchmann P, Engert A, Bröckelmann PJ. Momotow J, et al. Among authors: buhnen i. Br J Haematol. 2022 Jul;198(2):401-404. doi: 10.1111/bjh.18231. Epub 2022 May 11. Br J Haematol. 2022. PMID: 35538912 No abstract available.
Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group.
Eichenauer DA, Bühnen I, Plütschow A, Kobe C, Dietlein M, Wendtner CM, Thorspecken S, Topp MS, Mauser M, von Tresckow B, Fuchs M, Borchmann P, Engert A. Eichenauer DA, et al. Among authors: buhnen i. Hematol Oncol. 2022 Oct;40(4):801-804. doi: 10.1002/hon.2986. Epub 2022 Mar 24. Hematol Oncol. 2022. PMID: 35313381 Clinical Trial. No abstract available.
Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma.
Kreissl S, Voltin CA, Kaul H, Bühnen I, Mettler J, Pabst T, Eichenauer DA, Fuchs M, Diehl V, Dietlein M, Engert A, Borchmann P, Kobe C. Kreissl S, et al. Among authors: buhnen i. Br J Haematol. 2022 Apr;197(1):e5-e8. doi: 10.1111/bjh.17997. Epub 2021 Dec 20. Br J Haematol. 2022. PMID: 34929056 No abstract available.
Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group.
Eichenauer DA, Bühnen I, Kreissl S, Goergen H, Fuchs M, von Tresckow B, Rosenwald A, Klapper W, Hansmann ML, Möller P, Bernd HW, Feller AC, Engert A, Borchmann P, Hartmann S. Eichenauer DA, et al. Among authors: buhnen i. Br J Haematol. 2022 Jan;196(1):99-104. doi: 10.1111/bjh.17770. Epub 2021 Aug 15. Br J Haematol. 2022. PMID: 34396513 Clinical Trial.
PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study.
Eichenauer DA, Kreissl S, Bühnen I, Baues C, Kobe C, van Heek L, Goergen H, Fuchs M, Hartmann S, von Tresckow B, Engert A, Borchmann P. Eichenauer DA, et al. Among authors: buhnen i. Ann Oncol. 2021 Jun;32(6):807-810. doi: 10.1016/j.annonc.2021.02.018. Epub 2021 Mar 3. Ann Oncol. 2021. PMID: 33667668 Free article. No abstract available.